IRIDEX (NASDAQ:IRIX) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report report published on Wednesday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Down 9.3 %

IRIX opened at $0.86 on Wednesday. The firm has a market cap of $14.47 million, a price-to-earnings ratio of -1.29 and a beta of 0.94. IRIDEX has a 52 week low of $0.78 and a 52 week high of $3.65. The business’s 50 day moving average is $1.30 and its two-hundred day moving average is $1.55. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Thursday, March 27th. The medical equipment provider reported ($0.05) EPS for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $12.70 million for the quarter, compared to analysts’ expectations of $12.80 million. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.